Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MORU’s Lao PDR targeted malaria elimination (TME) team recently installed 8 hand pumps to provide safe drinking water in 4 villages in Nong District, Savannakhet Province after villagers requested the pumps in return for participating in a TME project.

Children pumping up water and drinking it

Funded by the Bill and Melinda Gates Foundation, the TME project seeks to accelerate malaria elimination by providing mass drug administrations to communities with a relatively high P. falciparum prevalence that are covered by village health malaria workers and which have access to long lasting insecticide treated bed nets.

Gates funded TME project operates in four Greater Mekong Subregion countries: Myanmar, Cambodia, Lao PDR and Viet Nam. LOMWRU’s Dr Mayfong Mayxay is the principal investigator (PI) for the Lao PDR study, while Dr Koukeo Phommasone is the field site PI.

Savannakhet has the third highest malaria incidence of Laos’ 18 provinces. A survey conducted in 18 rural Savannakhet villages in 2015 using uPCR detected Plasmodium infections in 175 of 888 samples (20%). Most villages in Savannakhet are relatively accessible and malaria elimination is a high priority for the local government.

A pilot project to eliminate malaria was initiated in four villages in April 2016. The project showed that mass drug administration (MDA) in Savannakhet is feasible and well accepted, with more than 80% of the targeted villagers participating in three rounds of drug administrations.

The drug regimen consists of three monthly rounds (M0, M1 and M2) of three daily treatment doses of DHA/piperaquine (7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine phosphate) combined with a single low dose primaquine (15mg or 0.25mg/kg). Frequency and timing of the MDA rounds relates to the modeled maximum effects on transmission reduction and the post-treatment prophylactic effect of piperaquine, which is around 30 days in sensitive strains.

All residents in the study villages are encouraged to take part in three rounds except for women in the first trimester of pregnancy and children under 6 months of age. A single low dose primaquine is sufficient to clear rapidly gametocytes which are not susceptible to schizontocidal drugs but does not clear hypnozoites and therefore does not prevent P. vivax relapses. During the MDAs, all drugs were administered under direct observation of study staff.

Similar stories

Pint of Science Thailand is back, now online

MORU Public Engagement

Live and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!

We gathered rich insights into child survival in Kenya by mapping patterns over 22 years

KWTRP Research

Although improvements in child survival globally have been remarkable, 5.2 million children still died in 2019, over half of these in sub-Saharan Africa. A range of factors likely include disparities in childhood immunisations, supplements and breastfeeding practices, antenatal care, skilled birth attendants working in healthcare facilities. Kenya needs to prioritise its child care plans, based on localities and populations with the greatest need. Two KWTRP studies give granular insights into the situation in regions across Kenya.

Innovative strategies for engaging communities with malaria research

MORU Public Engagement

For World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.

New project’s child-appropriate primaquine doses could have significant impact on global burden of malaria

MORU

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.